Your search returned 9 results

{0} results
{0} result

Blog Post

The Netherlands: specific exemption notification for medical devices in case of a no-deal Brexit

08 April 2019

To ensure that medical devices certified by a UK Notified Body can still be imported into the Netherlands after a no-deal Brexit, an exemption procedure has been drawn up by the Dutch...

Blog Post

While EMA is operating from Amsterdam as of March, we present Alexander Roussanov who joined Hogan Lovells from EMA

29 March 2019

As of 11 March 2019, the European Medicines Agency (EMA) is operating from Amsterdam. EMA's seat formally changes from London to Amsterdam on 30 March. A week after starting operations from ...

Blog Post

Pharmacy compounding of patented medicines in the Netherlands

18 February 2019

The pharmacy exemption came into force on 1 February 2019

Blog Post

Update EMA relocation to Amsterdam & regulatory changes for EU centrally approved medicinal products

12 February 2019

As the European Medicines Agency (EMA) is relocating from London to Amsterdam in view of Brexit, several developments took place during the last few weeks:

Blog Post

EMA office in Amsterdam opened – Wooden shoes, orphan drugs and drug pricing in the context of Brexit

11 January 2019

On 9 January 2019, the European Medicines Agency (EMA) opened its office in Amsterdam, the Netherlands. As the UK will leave the EU 29 March 2019 due to Brexit, the EMA is relocating from...

Blog Post

The European Commission is considering opening an antitrust probe for parallel imports in the pharmaceutical sector

17 May 2018

The European Commission is looking into several parallel imports cases, including in the life sciences industry, with a view to opening formal antitrust investigations, which may eventually ...

Blog Post

Biosimilar switching: Dutch MoH announces the set-up of a national system for biological medicinal products

25 May 2016

The Dutch Minister of Health (MoH) announced the set-up of a national system to trace the safety of biological medicinal products. The MoH expects an increase in the number of biosimilar...

Blog Post

Netherlands MEB revises position on biosimilars and interchangeability

13 April 2015

The Dutch Medicines Evaluation Board (MEB) published a new position on biosimilars, in which it accepts substitution or interchangeability of biosimilars under certain conditions. The...

Blog Post

Dutch Sunshine Act: Financial relations between pharmaceutical companies and healthcare professionals will be made public in the Netherlands in April

20 March 2013

As of 10 April 2013, the transparency register regarding financial relations between pharmaceutical companies and healthcare professionals in the Netherlands will go live.  Through the...

No results found for the matching keyword.

;
Loading data